Latest News
& Press Releases
Browse the latest news from BioSpace, and press releases from around the industry. Want to filter by date, keyword, and more? Search here.
TOP STORIES
Sandoz hopes its high-concentration formulation of an already greenlit biosimilar will be approved by the time AbbVie’s blockbuster drug Humira loses patent protection in the United States.
According to a study, people with certain gut disorders may be at greater risk of Alzheimer’s disease, and researchers have discovered a potential use for ASOs against cystic fibrosis.
As Severin Schwan prepares to step aside from the day-to-day leadership of Roche, Thomas Schinecker is waiting in the wings to assume the company’s top leadership spot.
A new study published in Frontiers in Aging Neuroscience by researchers at Tufts University further supports the theory that there’s a link between gum disease and Alzheimer’s.
Vertex and Verve announced they had entered an exclusive four-year research partnership to discover and nurture a gene editing therapy for yet-undisclosed liver disease.
With a deep knowledge of the urology space, Urovant is developing a unique approach to treating overactive bladder - an injectable plasmid human cDNA encoding maxi-K channel gene therapy.
Hansa Biopharma secured $70 million in non-dilutive financing, OSE secured $300 million in funding while CN Bio opened a new contract research facility and more global biopharma news.
As monkeypox continues to spread across the globe, health experts suggest monitoring vaccine effectiveness, population spread and at-risk groups.
The new chief executive officer of Versanis is going to push the obesity drug bimagrumab in the limelight against Novo and Lilly’s drug. Here’s all that you need to know.
Total sales for the quarter were $12.8 billion, with its innovative medicines, which include key assets, bringing in $10.8 billion.
Auron Therapeutics reels in $48 million to identify novel AI-based cancer targets, Frontera scoops up $160 million for AAV gene therapy and tech manufacturing and MMI scores $75 million for robotic microsurgery.
CAMP4 Therapeutics raised another $100 million in financing to advance its approach into the “dark side of the genome” and drive two therapeutics into clinical trials next year.
PRESS RELEASES
Head-to-Head Study Highlights Rocbrutinib as the World’s First Fourth-Generation Dual Covalent and Non-Covalent BTK Inhibitor Designed to Overcome Resistance Mutations
Corporate Treasury Positioned with Cash and Liquid Equity Holdings to Seed, Incubate and Accelerate New and Existing Operations